항고혈압제 사용중 혈중지질의 변화

• Published in: The Korean journal of medicine Vol. 47; no. 1; pp. 57 - 65
• Main Authors: 김상욱, Sang Wook Kim, 송태호, Tae Ho Song, 김철우, Cheul Woo Kim, 권기익, Ki Ik Kwon, 유언호, Un Ho Ryoo
• Format: Journal Article
• Language: Korean
• Published: 대한내과학회 01.07.1994
• Subjects: Antihypertensive therapy; Serum lipid changes
• ISSN: 1738-9364

Background: Hypertension is a major risk factor for atherosclerotic vascular disease. Many antihypertensive drugs are known to alter lipoprotein metabolism and this may override the benefit of blood pressure reduction. The purpose of this study is to evaluate the effects of the antihypertensive therapy in serum lipid. Method: The clinical study was done on 200 patients with hypertension who treated with esidrex, beta-blocker, or esidrex plus beta-blocker as an antihypertensive medication. The patients were divided into three groups according to the antihypertensive regimens. The serum lipid values were checked before and during antihypertensive therapy. Average follow up period of serum lipid was about 2 years. Results : 1) The serum lipid values before antihypertensive therapy were triglyceride 177±125 mg/dl, HDL-cholesterol 42±12 mg/dl, total cholesterol 230±50 mg/dl, and 1 year after antihypertensive therapy, triglyceride 233±134 mg/dl, HDL-cholesterol 43±22 mg/dl, total cholesterol 235±47 mg/dl, and 2 year after antihypertensive therapy, triglyceride 243±172 mg/dl, HDL-cholesterol 45±11 mg/dl, total cholesterol 233±40 mg/dl. The serum triglyceride and total cholesterol were increased significantly after antihypertensive therapy. 2) In 30 patients with esidrex therapy, the serum total cholesterol was elevated than the pretreatment value (p<0.05); pretreatment value 228±59 mg/dl, 6 months 233±53 mg/dl, 1 year 239±53 mg/dl, 2 year 238±39 mg/ dl. 3) In 81 patients with beta-blocker therapy, the serum triglyceride was elevated than the pretreatment value (p<0.05); pretreatment value 164±67 mg/dl, 6 months 183±72 mg/dl, 1 year 245±75 mg/dl, 2 year 205±84 mg/ dl. 4) In 89 patients with esidrex plus beta-blocker therapy, the serum total cholesterol was elevated than pretreatment value (p<0.05); pretreatment value 210±45 mg/dl, 6 month 264±50 mg/dl, l year 237±53 mg/dl, 2 year 225±48 mg/di, and triglyceride was also elevated; pretreatment value 163±87 mg/dl, 6 months 195±76 mg/dl, 1 year 208±80 mg/dl, 2 year 211±85 mg/ dl, But the serum HDL cholesterol was not elevated significantly. Conclusion : The esidrex therapy was associated with the elevation of serum total cholesterol and beta- blocker therapy was associated with the elevation of serum triglyceride. The serum total cholesterol and triglyceride were increased during esidrex plus beta-blocker therapy.